Zusammenfassung
Quetiapin ist ein atypisches Neuroleptikum, das sowohl Positiv- als auch Negativsymptome
schizophrener Erkrankungen günstig beeinflusst, ohne extrapyramidalmotorische Nebenwirkungen
auszulösen oder die Kognition ungünstig zu beeinflussen. Es gibt mittlerweile vier
Fallberichte, sieben offene Studien, eine plazebokontrollierte, randomisierte Studie
und eine retrospektive Untersuchung zum Einsatz von Quetiapin bei akuten Manien und
therapierefraktären bipolaren Erkrankungen bei verschiedenen Patientengruppen. Insgesamt
scheint Quetiapin stimmungsstabilisierende Eigenschaften bei einem günstigen Verträglichkeitsprofil
zu haben. Doppelblinde, plazebokontrollierte Studien müssen jedoch durchgeführt werden,
um verbindliche Aussagen zum Einsatz von Quetiapin bei bipolaren Erkrankungen machen
zu können.
Summary
Quetiapine is a novel antipsychotic, which is efficacious in the treatment of positive
and negative symptoms in schizophrenia. It does neither worsen cognitive symptoms
nor does it exacerbate extrapyramidal motor symptoms. There are 4 case reports, 7
open studies, 1 placebo controlled randomized and 1 retrospective study investigating
its use in the treatment of bipolar disorder. Quetiapine seems to have mood stabilizing
properties and a good safety profile. Double-blind placebo controlled studies are
warranted to confirm these preliminary findings.
Literatur
- 1
Coryell W, Leon AC, Turvey C, Akiskal HS, Mueller T, Endicott J.
The significance of psychotic features in manic episodes: a report from the NIMH collaborative
study.
J Affect Disord.
2001;
67
79-88
- 2
Fennig S, Bromet EJ, Karant MT, Ram R, Jandorf L.
Mood-congruent versus mood-incongruent psychotic symptoms in first-admission patients
with affective disorder.
J Affect Disord.
1996;
37
23-29
- 3
Goodwin K. F., Jamison KR.
Manic-depressive illness.
New-York: Oxford University Press.
1990;
- 4
Swann AC, Janicak PL, Calabrese JR, Bowden CL, Dilsaver SC, Morris DD. et al. .
Structure of mania: depressive, irritable, and psychotic clusters with different retrospectively-assessed
course patterns of illness in randomized clinical trial participants.
J Affect Disord.
2001;
67
123-132
- 5
Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B.
Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder.
J Clin Psychopharmacol.
1998;
18
455-460
- 6
Tohen M, Hennen J, Zarate CM, Jr., Baldessarini RJ, Strakowski SM, Stoll AL. et al.
.
Two-year syndromal and functional recovery in 219 cases of first-episode major affective
disorder with psychotic features.
Am J Psychiatry.
2000;
157
220-228
- 7
Maj M, Pirozzi R, Bartoli L, Magliano L.
Long-term outcome of lithium prophylaxis in bipolar disorder with mood-incongruent
psychotic features: a prospective study.
J Affect Disord.
2002;
71
195-198
- 8
Weizman R, Weizman A.
Use of atypical antipsychotics in mood disorders.
Curr Opin Investig Drugs.
2001;
2
940-945
- 9
Lakshmi N, Yatham MBBS.
The role of novel antipsychotics in bipolar disorder.
J Clin Psychiatry.
2002;
63
10-14
- 10
Tohen M, Zarate CAJr.
Antipsychotic agents in bipolar disorder.
J Clin Psychiatry.
1998;
59
38-48
- 11
Brotman MA, Fergus EL, Post RM, Leverich GS.
High exposure to neuroleptics in bipolar patients: a retrospective review.
J Clin Psychiatry.
2000;
61
68-72
- 12
Nasrallah HA, Churchill CM, Hamdan-Alla GA.
Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia.
Am J Psychiatry.
1998;
145
1455-1456
- 13
Mukherjee S, Rosen AM, Caracci G, Shukla S.
Persistent tardive dyskinesia in bipolar patients.
Arch Gen Psychiatry.
1986;
43
342-346
- 14
Calabrese JR, Kimmel SE, Woyshville MJ.
Clozapine for the treatment of refractory mania.
Am J Psychiatry.
1996;
153
759-764
- 15
Segal J, Berk M, Brook S.
Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized
controlled trial.
Clin Neuropharmacol.
1998;
21
176-180
- 16
Sachs GS.
Safety and efficacy of risperidone versus placebo in combination with lithium or valproate
in the treatment of the manic phase of the bipolar disorder.
In J Neuropsychopharmacol.
2000;
3
143;
- 17
Kopala LC, Good KP, Honer WG.
Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response
to low-dose risperidone.
J Clin Psychopharmacol.
1997;
17
308-313
- 18
Peuskens J.
Risperidone in the treatment of patients with chronic schizophrenia: a multi-national,
multi-centre, double-blind, parallel-group study versus haloperidol.
Risperidone Study Group Br J Psychiatry.
1995;
166
712-726
- 19
Malhotra S, McElroy SL.
Medical management of obesity associated with mental disorders.
J Clin Psychiatry.
2002;
63
24-32
- 20
Tohen M, Sanger TM, McElroy SL.
Olanzapine versus placebo in the treatment of acute mania.
Am J Psychiatry.
1999;
156
702-709
- 21
Tohen M, Jacobs TG, Grundy SL.
The olanzapine HGGW Study Group. Efficacy of olanzapine in acute bipolar mania: a
double-blind, placebo-controlled study.
Arch Gen Psychiatry.
2000;
57
841-849
- 22
Sanger TM, Grundy SL, Gibson PJ.
Long-term olanzapine therapy in the treatment of bipolar-I disorder: an open-label
continuation-phase study.
J Clin Psychiatry.
2001;
62
273-281
- 23
Berk, Ichim L, Brook S.
Olanzapine compared to lithium in mania.: a double-blind randomized controlled trial.
Int Clin Psychopharmacol.
1999;
14
339-343
- 24
McIntyre RS.
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited.
J Clin Psychiatry.
2002;
63
3;
15-20
- 25
Arvanitis LA, Miller BG.
Multiple fixed doses of seroquel in patients with acute exacerbation of schizophrenia:
a comparison with haloperidol and placebo.
Biol Psychiatry.
1997;
42
233-246
- 26
Small JG, Hirsch SR, Arvanitis LA.
Quetiapine in patients with schizophrenia: a high and low dose double-blind comparison
with placebo.
Arch Gen Psychiatry.
1997;
54
549-557
- 27
Sajatovic M, Brescan DW, perez DE, DiGiovanni SK, Hattab H., Ray JB, Bingham CR.
Quetiapine anlone and added to a mood stabilizer for serious mood disorders.
J Clin Psychiatry.
2001;
62
728-732
- 28
Dunayevich E, Tugrul RN, Strakowski SM.
Quetiapine in the treatment of mania.
International Congress on Schizophrenia Research, Whistler.
2001;
- 29
Dunayevich E, Strakowski SM.
Quetiapine for treatment-resistant mania.
Am J Psychiatry.
2000;
157
1341
- 30
Altamura C, Madaro D, Salvadori D.
Quetiapine in acute mania: a case report (with a six-month follow-up).
Int J Psychiatry Clin Pract.
2001;
5
283-285
- 31
Zarate CA, Rothshild A, Fletcher KE, Madrid A, Zapatel J.
Clinical predictors of acute response with quetiapine in psychotic mood disorders.
J Clin Psychiatry.
2000;
61
185-189
- 32
Madhusoodanan S, Brenner R, Alcantra A.
Clinical experience with quetiapine in the elderly with psychotic diosrders.
J Geriatr Psychiatr Neurol.
2000;
13
18-32
- 33
Chisholm K, Dennehy E, Suppes T.
Clinical response to quetiapine add-on for treatment of refractory bipolar disorder.
Fourth International Conference on bipolar disorder, Pittsburgh, June.
2001;
- 34
Ghaemi SN, Katzow JJ.
The use of quetiapine for treatment-resistant bipolar disorder: a case series.
Ann Clin Psychiatry.
2000;
11
137-140
- 35
Schaller JL, Behar D.
Quetiapine for refractory mania in a child.
J Am Acad Child Adolesc Psychiatry.
1999;
38
498-499
- 36
Alston JF.
Remission of treatment-resistant bipolar disorder I with quetiapine in an adolescent.
7th World Congress of Biological Psychiatry, July.
2001;
- 37
DelBello MP, Schwiers ML, Rosenberg HL, Seshadri V, Wilhoit SR, Strakowski SM.
Quetiapine as adjunctive treatment to adolescent mania.
Fourth International Conference on bipolar disorder, Pittsburgh, June.
2001;
- 38
Ghaemi SN, Goldberg JF, Koo JY, McNally EE.
Quetiapine treatment of rapid cycling bipolar disorder: an open prospective study.
Fourth International Conference on Bipolar Disorder, Pittsburgh, June.
2001;
- 39
Brown ES, Nejtek VA, Perantie DC, Bobadilla L.
Quetiapine in patients with bipolar disorder and cocaine dependence.
4th International Conference on Bipolar Disorder, Pittsburgh, June.
2001;
Korrespondenzadresse
PD. Dr. med. Stephanie Krüger
Center for Addiction and Mental Health, Clarke Institute of Psychiatry
Mood and Anxiety Disorders Division and PET Center, University of Toronto, Canada
Email: Stephanie_Krueger@camh.net
